Events

DUT Conference 2024 – Driving Urban Transitions through Joint Action
APR
Wed
10
APR
Thu
11
APR
Fri
12

This was 1 year ago

Location

Hybrid event

Area 42
Rue des Palais 46
1030 Brussels
Belgium
Programmes
Climate, Energy, Mobility Missions

The Driving Urban Transitions Partnership aims to bring together urban leaders, practitioners, researchers, investors, and visionaries at the forefront of sustainable urban transitions for three days of collaborative learning and discussions. 

The following events and activities will take place within those three days:

  • DUT’s biennial policy conference 2024: Driving Urban Transitions through Joint Action, with DUT Open Area and Festival - join onsite or online
  • AGORA Strategic Dialogue: Empowering Urban Futures: Bridging Policy, Innovation, and Local Action (onsite only)
  • DUT Call 2022 projects kick-off event (by invitation only)


More information, the detailed programme and registration to the DUT conference here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.